Modeling and simulation of bone mineral density in Japanese osteoporosis patients treated with zoledronic acid using tartrate-resistant acid phosphatase 5b, a bone resorption marker
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1433-2965
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Modeling and simulation of bone mineral density in Japanese osteoporosis patients treated with zoledronic acid using tartrate-resistant acid phosphatase 5b, a bone resorption marker ; day:8 ; month:2 ; year:2018 ; pages:1-9
Osteoporosis international ; (8.2.2018), 1-9
- Keyword
-
Orthopädie
- Creator
-
Mori, Y.
- Contributor
-
Kasai, H.
Ose, A.
Serada, M.
Ishiguro, M.
Shiraki, M.
Tanigawara, Y.
SpringerLink (Online service)
- DOI
-
10.1007/s00198-018-4376-1
- URN
-
urn:nbn:de:1111-201804158942
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:51 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Mori, Y.
- Kasai, H.
- Ose, A.
- Serada, M.
- Ishiguro, M.
- Shiraki, M.
- Tanigawara, Y.
- SpringerLink (Online service)
Other Objects (12)
Topical zoledronic acid decreases micromotion induced bone resorption in a sheep arthroplasty model
Local treatment of a bone graft by soaking in zoledronic acid inhibits bone resorption and bone formation. A bone chamber study in rats
Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells
Bone targeting compounds for radiotherapy and imaging: *Me(III)-DOTA conjugates of bisphosphonic acid, pamidronic acid and zoledronic acid
Various pathways of zoledronic acid against osteoclasts and bone cancer metastasis: a brief review
An Acid‐Activatable Fluorescence Probe for Imaging Osteocytic Bone Resorption Activity in Deep Bone Cavities
A combination of methotrexate and zoledronic acid prevents bone erosions and systemic bone mass loss in collagen induced arthritis
Zoledronic acid is more efficient than ibandronic acid in the treatment of symptomatic bone marrow lesions of the knee
Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study
Effects of zoledronic acid on bone structure and organization of nanocomposites in rats with obesity and limited mobility
In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease
Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment
Topical zoledronic acid decreases micromotion induced bone resorption in a sheep arthroplasty model
Local treatment of a bone graft by soaking in zoledronic acid inhibits bone resorption and bone formation. A bone chamber study in rats
Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells
Bone targeting compounds for radiotherapy and imaging: *Me(III)-DOTA conjugates of bisphosphonic acid, pamidronic acid and zoledronic acid
Various pathways of zoledronic acid against osteoclasts and bone cancer metastasis: a brief review
An Acid‐Activatable Fluorescence Probe for Imaging Osteocytic Bone Resorption Activity in Deep Bone Cavities
A combination of methotrexate and zoledronic acid prevents bone erosions and systemic bone mass loss in collagen induced arthritis
Zoledronic acid is more efficient than ibandronic acid in the treatment of symptomatic bone marrow lesions of the knee
Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study
Effects of zoledronic acid on bone structure and organization of nanocomposites in rats with obesity and limited mobility
In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease
Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment
Topical zoledronic acid decreases micromotion induced bone resorption in a sheep arthroplasty model
Local treatment of a bone graft by soaking in zoledronic acid inhibits bone resorption and bone formation. A bone chamber study in rats
Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells
Bone targeting compounds for radiotherapy and imaging: *Me(III)-DOTA conjugates of bisphosphonic acid, pamidronic acid and zoledronic acid
Various pathways of zoledronic acid against osteoclasts and bone cancer metastasis: a brief review
An Acid‐Activatable Fluorescence Probe for Imaging Osteocytic Bone Resorption Activity in Deep Bone Cavities
A combination of methotrexate and zoledronic acid prevents bone erosions and systemic bone mass loss in collagen induced arthritis
Zoledronic acid is more efficient than ibandronic acid in the treatment of symptomatic bone marrow lesions of the knee
Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study
Effects of zoledronic acid on bone structure and organization of nanocomposites in rats with obesity and limited mobility
In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease